NEW YORK, Aug. 16, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that enrollment has opened at 65 of the 70 sites that will participate in the first pivotal Phase III trial of VEN 309 for the treatment of symptomatic hemorrhoids, and patients have now entered the screening process. Ventrus expects that the dosing of the first patients will begin the week of August 22 2011, and that the remaining 5 sites will be initiated in the current quarter. "We are excited to begin the pivotal Phase III trial for VEN 309 for the treatment of hemorrhoids, as planned," said Russell H. Ellison MD, Chairman and CEO of Ventrus, "particularly as this is the first Phase III trial in the U.S. for a drug treatment for patients with this condition, for whom there are currently no FDA-approved prescription drugs available."
